In8Bio (INAB) Preferred Stock Liabilities (2020 - 2021)
In8Bio (INAB) posted Preferred Stock Liabilities of $34.9 million for Q2 2021, little changed sequentially from $34.9 million in Q1 2021, and up 143.09% YoY from $14.4 million in Q2 2020.
In8Bio (INAB) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
In8Bio has reported Preferred Stock Liabilities for 2 years, with the latest figure at $34.9 million in Q2 2021.
- Quarterly Preferred Stock Liabilities rose 143.09% year-over-year to $34.9 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $34.9 million (up 143.09% YoY) and the FY2020 annual result came in at $34.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $34.9 million in Q2 2021 per INAB's latest filing, from $34.9 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $34.9 million in Q4 2020 and troughed at $14.4 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 34.90 Mn |
| Mar 31, 2021 | 34.90 Mn |
| Dec 31, 2020 | 34.90 Mn |
| Sep 30, 2020 | 34.07 Mn |
| Jun 30, 2020 | 14.36 Mn |